wire - news in brief

« BACK

Life Sciences



Results 1 - 50 of 810.
1 2 3 4 5 ... 17 Next »


Life Sciences - 19.11.2018
Precise synaptic organization of a memory network
Precise synaptic organization of a memory network
In order to examine how synaptic inputs to individual neurons are organized in a distributed memory network, researchers from the Friedrich group performed electrophysiological recordings in the zebrafish homolog of the olfactory cortex. They found that large excitatory inputs were paired with large inhibitory inputs, which may seem counterintuitive because inhibition cancels excitation.

Environment - Life Sciences - 01.11.2018
Wyss Foundation supports the University of Bern
Wyss Foundation supports the University of Bern
The Wyss Foundation announced yesterday that it will begin a global conservation campaign. On a related note, they also announced that they will be working on a year-long pilot project in Kenya and Peru, together with the University of Bern.

Health - Life Sciences - 01.11.2018
Andrea Ablasser wins the 2018 National Latsis Prize
The medical researcher and EPFL professor Andrea Ablasser , who studies how cells defend themselves against viral and bacterial attacks, has won the 2018 National Latsis Prize in recognition of her excellent research work on immunity.

Life Sciences - 01.11.2018

Health - Life Sciences - 01.11.2018
Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence
Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence
The medical researcher and EPFL professor Andrea Ablasser studies how cells defend themselves against viral and bacterial attacks.

Health - Life Sciences - 30.10.2018
Switzerland-wide platform for cell therapy launched in Bern
Regenerative Medicine is one of the fastest growing sectors in biomedical research - replacing diseased cells, tissues or organs.

Life Sciences - Health - 26.10.2018
Subsides d’encouragement de projets de recherche FNS: 26 projets UNIL-CHUV acceptés - News
Subsides d'encouragement de projets de recherche FNS: 26 projets UNIL-CHUV acceptés Lors de la dernière session de printemps 2018, 26 projets de recherche UNIL-CHUV ont été financés par le FNS.

Health - Life Sciences - 24.10.2018

Life Sciences - Health - 23.10.2018
The epigenetics of cartilage repair and regeneration
The European Research Council (ERC) has awarded a prestigious ERC Synergy Grant - perhaps the most competitive funding scheme from ERC - to the research groups of Prof. Filippo Rijli from the

Health - Life Sciences - 19.10.2018
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC)   Clinical findings from ongoing study indicate safety prof

Health - Life Sciences - 16.10.2018
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) ,   In rheumatolo

Health - Life Sciences - 10.10.2018
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg   Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial   Treatment discontinuations were overall more common in the

Health - Life Sciences - 08.10.2018
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d

Life Sciences - 05.10.2018
Congratulations to the FMI Prize winners 2018
As in previous years, several internal prizes were awarded during the FMI Annual Meeting, a 3 day scientific meeting attended by most scientists in the institute.

Health - Life Sciences - 03.10.2018
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam

Life Sciences - 27.09.2018
Fructose metabolism and noncommunicable diseases: recent findings and new research perspectives
Prof. Luc Tappy, Department of Physiology Fructose is a physiological nutrient which, when consumed in excess, may have adverse metabolic effects, mainly in the liver (hepatic insulin resistance and fat storage).

Health - Life Sciences - 24.09.2018
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many cancer patients have insufficient or inadequate tissue for genomic t

Health - Life Sciences - 19.09.2018
University of Basel and ETH Zurich combine cutting-edge research for children and adolescents worldwide
University of Basel and ETH Zurich combine cutting-edge research for children and adolescents worldwide
Today, the University of Basel and ETH Zurich co-founded the Botnar Research Centre for Child Health (BRCCH) in Basel.

Life Sciences - 18.09.2018

Careers / Employment - Life Sciences - 18.09.2018
Marie Heim-Vögtlin Prize 2018: Sara Montagner discovers the epigenetic secrets of mast cells
Epigenetic modifications of our DNA are a key aspect of the normal functioning of mast cells, which play an important role in immune reactions. Biologist Sara Montagner was able to demonstrate this in her work. She will receive this year's Marie Heim-Vögtlin Prize from the SNSF at the award ceremony in Bellinzona on 29 November 2018.

Health - Life Sciences - 18.09.2018
University of Basel and ETH Zurich Combine Cutting-Edge Research for Children and Adolescents Worldwide
Today, the University of Basel and ETH Zurich co-founded the Botnar Research Centre for Child Health (BRCCH) in Basel.

Health - Life Sciences - 13.09.2018
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya in children and adolescents with MS
Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs.

Health - Life Sciences - 13.09.2018
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx in daily life for psoriasis patients
Real-world evidence confirms Cosentyx efficacy and safety consistent with previously reported clinical studies - Novartis presents a large program of real-world evidence at the 27 th European Academy of Dermatology and Venereology (EADV) Congress, adding to the robust body of clinical data supporting the use of Cosentyx in moderate-to-severe psoriasis - Cosentyx 5-year data in psoriasis from a Phase III study were presented in 2017 , proving lon

Health - Life Sciences - 12.09.2018
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no injection site reactions A separate ranking incorporating additional characteristics showed that effectiveness in treating multiple manifestations of psoriatic disease was also important The number of injections per dose and injection frequency were least imp

Life Sciences - Health - 07.09.2018
Using biosensors to deliver personalized doses of antibiotics
A team of eight EPFL students won the technical prize in the SensUs international competition, designing a portable biosensor that can measure the amount of vancomycin in a patient's blood stream, enabling doctors to better control the dosage and reduce harmful side effects.

Health - Life Sciences - 06.09.2018
A new home for ETH's Department in Basel
A new home for ETH’s Department in Basel
Today ETH Zurich celebrated the laying of the foundation stone for its new building on the Schällemätteli campus in Basel.

Life Sciences - 06.09.2018
ETH professor not guilty of manipulation
An independent commission of inquiry led by the French National Center for Scientific Research (CNRS) with the participation of ETH Zurich has investigated the publications of ETH Professor Olivier Voinnet's former research group at the CNRS. The inquiry uncovered manipulation of certain figures. However, the commission's report confirms that Voinnet did not personally initiate this manipulation.

Environment - Life Sciences - 03.09.2018
Art inspired by research - new AiL videos
Art inspired by research - new AiL videos
In 2017, two artists from Saudi Arabia spent some time at Eawag as part of the Artists in Labs (ail) project and were inspired by research into artistic interpretations, Zahrah Alghamdi and Muhannad Shono.

Health - Life Sciences - 29.08.2018
European Commission approves Novartis combination therapy Tafinlar + Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients    More than 50% of stage III melanoma patients are lik

Health - Life Sciences - 27.08.2018
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r

Life Sciences - 23.08.2018
Motor cortex needed for sensory-guided control of movement
Motor cortex needed for sensory-guided control of movement
In a collaboration, Matthias Heindorf (FMI/Biozentrum), Silvia Arber (FMI/Biozentrum), and Georg Keller (FMI) investigated the role of motor cortex in the control of movement. Their study - published in ‘Neuron' today - demonstrates that motor cortex is necessary for the execution of corrective movements in response to unexpected changes of sensory input but not when the same movements are executed spontaneously.

Life Sciences - 23.08.2018
Movement control: how our brain responds to unexpected situations
Movement control: how our brain responds to unexpected situations
Scientists have demonstrated that the motor cortex is necessary for the execution of corrective movements in response to unexpected changes of sensory input but not when the same movements are executed spontaneously.

Health - Life Sciences - 03.08.2018
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting the underlying cause of Huntington's disease, a fatal neurodegenerative rare disease Third PRIME designation for a Roche medicine Roche today announced that the European Medicines Agency (E

Life Sciences - Environment - 25.07.2018
Scientists set out to explore microbial life in glacier streams
EPFL scientists will spend at least the next four years studying some of the world's biggest glacier-fed streams.

Health - Life Sciences - 23.07.2018
Novartis renews drug donation of Egaten (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 millio

Pharmacology - Life Sciences - 20.07.2018
Roche to present new data demonstrating the breadth and depth of its Alzheimer’s programme at the upcoming Alzheimer’s Association International Conference
Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference Late-breaking Phase II exploratory analysis

Life Sciences - Pharmacology - 20.07.2018
FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease
FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease Roche announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys ß-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF.

Health - Life Sciences - 18.07.2018
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Kisqal

Life Sciences - 18.07.2018
New EMBO and HFSP fellows at FMI
This summer four FMI postdocs have been awarded an EMBO fellowship and one an HFSP fellowship. These fellowships spark huge interest among young researchers but are rare, and hard to get.

Life Sciences - 10.07.2018
Wyss Center showcases research at La Nuit de la Science
Wyss Center showcases research at La Nuit de la Science
Campus Biotech joined forces with La Nuit de la Science for the first time and welcomed visitors onto campus for the duration of the two-day event The Wyss Center team showcased a new virtual reality

Environment - Life Sciences - 05.07.2018
Improving small hydropower planning
Improving small hydropower planning
Small hydropower plants are often constructed on alpine streams, where they may have adverse impacts on sensitive ecosystems. Little is known, however, about the particular effects of individual plants, or the cumulative effects of multiple plants within the same river system. The current state of knowledge has now been reviewed in a study by Eawag researchers.

Health - Life Sciences - 29.06.2018
Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe
Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe First CHMP opinion for a CAR-T cell therapy in

Health - Life Sciences - 21.06.2018
Claudia Daubenberger Appointed Professor at the University of Basel
Claudia Daubenberger Appointed Professor at the University of Basel
The University of Basel appointed Claudia Daubenberger, Head of Clinical Immunology at Swiss TPH, as professor of Infection Biology and Immunology within the Faculty of Science.

Health - Life Sciences - 16.06.2018
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable   Patients had a 65% chance of being relapse-free o
1 2 3 4 5 ... 17 Next »